S18 Ep4: Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Targeted therapies and immunotherapies are transforming the treatment landscape for advanced non-small cell lung cancer by addressing specific genomic alterations and immune evasion mechanisms. ROS1 and RET inhibitors have evolved significantly, with newer agents like talotrectinib and repotrectinib demonstrating superior progression-free survival and efficacy against resistance mutations such as G2032R. In the KRAS-mutant space, the shift from G12C-specific "off-state" inhibitors toward potent "on-state" and pan-RAS inhibitors offers expanded therapeutic options, with G12D-targeted agents emerging as a potential future standard. Simultaneously, immunotherapy is advancing through bispecific antibodies targeting PD-1/PD-L1 and VEGF, as well as innovative cellular therapies like tumor-infiltrating lymphocytes and CAR-T constructs. These developments provide critical pathways for patients with refractory disease, though they necessitate careful management of unique toxicities and complex clinical logistics.